1. Home
  2. |Insights
  3. |FCA Defendant Wins Attorneys’ Fees and the Government Gets Stuck with the Bill

FCA Defendant Wins Attorneys’ Fees and the Government Gets Stuck with the Bill

Client Alert | 1 min read | 08.23.17

In United States ex rel. Wall v. Circle C Constr., LLC (Aug. 18, 2017), the Sixth Circuit held that the defendant in a False Claims Act case brought by the government was entitled to recover nearly a half-million dollars in attorneys’ fees under § 2412(d)(1)(D) of the Equal Access to Justice Act. The panel majority found that the government’s original demand for damages ($1.66 M) was substantially in excess of the judgment finally obtained ($14,748) thus entitling the defendant, Circle C Construction, to the fees and other expenses related to defending against the government’s excessive demand in a case based on Davis-Bacon Act violations of one of Circle C’s subcontractors. Section 2412(d)(1)(D) of the Equal Access to Justice Act provides that in certain cases, defendants whose net worth falls below specified thresholds may recover costs associated with defending against an “excessive demand” by the government.


Finding the government’s original demand unreasonable because it was not substantially justified, the Sixth Circuit cited its 2016 decision (previously reported here), in which it rejected the government’s damages calculation and observed that the damages sought by the government were “fairyland” rather than actual.

Insights

Client Alert | 2 min read | 09.18.25

FDA Announces Intention to Initiate an Aggressive Enforcement Campaign Against Misleading Pharmaceutical Advertising

On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”...